Pharmaceuticals

Global Viral Vectors And Plasmid DNA Market 2026–2030: Forecast Insights for Business Planning

February 20, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the viral vectors and plasmid dna market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Viral Vectors And Plasmid DNA Market between 2026 and 2030?

The viral vectors and plasmid dna market size has seen strong growth in recent years. Projections indicate it will expand from $1.38 billion in 2025 to $1.47 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.2%. The growth witnessed historically can be linked to several factors, including the constrained availability of viral vectors, the reliance on research-grade plasmid DNA, the expansion of gene therapy pipelines, increasing biopharmaceutical R&D activities, and the adoption of conventional viral vector platforms.

The viral vectors and plasmid dna market size is anticipated to experience substantial growth in the upcoming years. It is forecast to climb to $1.89 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.6%. This expansion during the projection period stems from the advancement of clinical-grade and GMP plasmid DNA, the wider application of viral vectors in combating cancer and infectious diseases, increasing financial input into gene therapy, a rising need for immunotherapy solutions, and the adoption of new vector platforms such as AAV and lentiviral vectors. Key developments during the forecast period include the increasing incorporation of plasmid DNA and viral vectors in gene therapy, the broadening scope of viral vector platforms for cancer and genetic disorder treatments, a rise in GMP-grade plasmid DNA production for clinical purposes, enhanced research into novel adeno-associated and lentiviral vectors, and the integration of plasmid DNA and viral vectors in immunotherapy and vaccine creation.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3245&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Viral Vectors And Plasmid DNA Market?

The growing number of tuberculosis (TB) infections is anticipated to boost the expansion of the viral vector and plasmid DNA market in the future. Tuberculosis (TB) is an infectious condition that is contagious, potentially severe, and caused by bacteria. While primarily impacting the lungs, it can also extend its effects to other bodily systems. Plasmid DNA vaccines have found application in delivering microbial antigen-coding genes for tuberculosis treatment. Such vaccines can be engineered to express particular antigens of Mycobacterium tuberculosis, the bacterium responsible for tuberculosis, and are administrable via intramuscular injection. As an illustration, data from GOV.UK, a UK-based government department, revealed in February 2024 that tuberculosis (TB) cases in England saw a 10.7% increase in 2023, climbing from 4,380 in 2022 to 4,850. Consequently, the rising occurrence of tuberculosis cases is fueling the growth of the viral vector and plasmid DNA market.

How Is The Viral Vectors And Plasmid DNA Market Organized Into Various Segments?

The viral vectors and plasmid dna market covered in this report is segmented –

1) By Product: Plasmid DNA, Viral Vectors

2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases

3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications

4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies

Subsegments:

1) By Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA

2) By Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors

How Are Emerging Trends Affecting The Progression Of The Viral Vectors And Plasmid DNA Market?

Leading companies within the viral vectors and plasmid DNA market are increasingly focusing on introducing innovative products, such as helper plasmids, to gain a competitive edge. A helper plasmid is a form of plasmid DNA essential for the production of viral vectors, including adeno-associated viral vectors (AAV), commonly employed in gene therapy. For instance, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical company, launched its off-the-shelf pHelper. This helper plasmid aims to accelerate the process from early discovery to commercial manufacture for adeno-associated virus (AAV)-based gene therapy programs and ensure secure supplies. As the newest offering among a broad range of contract development and manufacturing organization (CDMO) goods and services, helper plasmids are designed to protect viral vector packaging in cell and gene therapy operations and streamline complex supply chains. Ultimately, adeno-associated viral vectors (AAV), which are frequently utilized in gene therapy, are indeed created using helper plasmids.

Who Are The Primary Competitors In The Global Viral Vectors And Plasmid DNA Market?

Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k? ??r??r?t??n, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Viral Vectors And Plasmid DNA Market?

North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Viral Vectors And Plasmid DNA Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3245&type=smp

Browse Through More Reports Similar to the Global Viral Vectors And Plasmid DNA Market 2026, By The Business Research Company

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Hospital Acquired Infections Testing Kits Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795